富士萊(301258.SZ):目前暫未涉及減肥藥相關產品
格隆匯2月21日丨富士萊(301258.SZ)於投資者互動平臺表示,公司目前暫未涉及減肥藥相關產品。在抗腫瘤領域,公司已取得重要進展,甲磺酸阿帕替尼是一種小分子酪氨酸激酶抑制劑,可抑制腫瘤血管生成。目前公司甲磺酸阿帕替尼原料藥已經通過CDE審批,表明該原料藥符合中國相關藥品審評技術標準,已批準在國內上市制劑中使用,將進一步豐富公司的產品線,提升公司競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.